1 |
World Health Organization. Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework; 2016 [cited 2021 Mar 1]. Available from: https://apps.who.int/iris/handle/10665/204790.
|
2 |
Umutesi G, Shumbusho F, Kateera F, Serumondo J, Kabahizi J, Musabeyezu E, et al. Rwanda launches a 5-year national hepatitis C elimination plan: a landmark in sub-Saharan Africa. J Hepatol 2019;70(6):1043-1045.
DOI
|
3 |
Devi S. Ukrainian health authorities adopt hepatitis C project. Lancet 2020;396(10246):228.
DOI
|
4 |
Douglass CH, Pedrana A, Lazarus JV, 't Hoen EF, Hammad R, Leite RB, et al. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med 2018;16(1):175.
DOI
|
5 |
Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics 2016;34(6):551-567.
DOI
|
6 |
Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, et al. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30. Lancet Glob Health 2019;7(9):e1180-e1188.
DOI
|
7 |
Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, et al. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol Hepatol 2020;5(10):940-947.
DOI
|
8 |
World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection; 2018 [cited 2021 Mar 1]. Available from: https://www.who.int/publications/i/item/9789241550345.
|
9 |
Scherz N, Bruggmann P, Brunner N. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment. Int J Drug Policy 2018;62:74-77.
DOI
|
10 |
Global Commission on Drug Policy. The negative impact of the war on drugs on public health: the hidden hepatitis C epidemic; 2013 [cited 2021 Jul 1]. Available from: https://www.drugsandalcohol.ie/28474/1/GCDP_HepatitisC_2013_EN.pdf.
|
11 |
Blindenbacher R, Maeschli B, Bruggmann P. The Swiss hepatitis strategy as a model for facing future health policy challenges. Health Policy 2019;123(7):681-687.
DOI
|
12 |
Jhaveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM. Universal screening of pregnant women for hepatitis C: the time is now. Clin Infect Dis 2018;67(10):1493-1497.
DOI
|
13 |
Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol 2018;69(4):785-792.
DOI
|
14 |
Younossi ZM, Stepanova M, Henry L, Younossi I, Weinstein A, Nader F, et al. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. J Viral Hepat 2016;23(8):623-630.
DOI
|
15 |
Lindgren P, Lofvendahl S, Bradvik G, Weiland O. Reduced work absenteeism in patients with hepatitis C treated with secondgeneration direct-acting antivirals. J Viral Hepat 2021;28(1):142-146.
DOI
|
16 |
Kind J, Maeschli B, Bruggmann P. In the shadow of HIV: the Cinderella hepatitis C. Suchtmed 2019;21(3):103-110.
|
17 |
Negro F, Weis N, Lazaru J. EASL policy statement hepatitis C elimination; 2019 [cited 2021 Jul 10]. Available from: https://easl.eu/wp-content/uploads/2019/07/EASL-Policy-Statement-on-Hepatitis-C-Elimination_June2019.pdf.
|
18 |
Australian Government Department of Health. Fifth national hepatitis C strategy 2018-2022; 2018 [cited 2021 Jul 1]. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/$File/Hep-C-Fifth-Nat-Strategy-2018-22.pdf.
|
19 |
Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int 2020;40(3):522-529.
DOI
|
20 |
Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, et al. Global hepatitis C elimination: an investment framework. Lancet Gastroenterol Hepatol 2020;5(10):927-939.
DOI
|
21 |
Maticic M, Pirnat Z, Leicht A, Zimmermann R, Windelinck T, Jauffret-Roustide M, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J 2020;17(1):89.
DOI
|
22 |
Yang S, Wang D, Zhang Y, Yu C, Ren J, Xu K, et al. Transmission of hepatitis B and C virus infection through body piercing: a systematic review and meta-analysis. Medicine (Baltimore) 2015;94(47):e1893.
DOI
|
23 |
Prati D. Transmission of viral hepatitis by blood and blood derivatives: current risks, past heritage. Dig Liver Dis 2002;34(11):812-817.
DOI
|
24 |
Cacoub P, Buggisch P, Carrion JA, Cooke GS, Zignego AL, Beckerman R, et al. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. J Viral Hepat 2018;25(7):811-817.
DOI
|
25 |
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17(2):107-115.
DOI
|
26 |
Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42(8):975-979.
DOI
|
27 |
Pozzetto B, Memmi M, Garraud O, Roblin X, Berthelot P. Health care-associated hepatitis C virus infection. World J Gastroenterol 2014;20(46):17265-17278.
DOI
|
28 |
Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis 2010;14(11):e928-e940.
DOI
|
29 |
Ward JW, Hinman AR. What Is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. Gastroenterology 2019;156(2):297-310.
DOI
|
30 |
Smith S, Harmanci H, Hutin Y, Hess S, Bulterys M, Peck R, et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017. JHEP Rep 2019;1(2):81-89.
DOI
|
31 |
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2(3):161-176.
DOI
|
32 |
Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc 2019;22(S6):e25348.
|
33 |
Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn 2017;17(12):1109-1115.
DOI
|
34 |
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017;166(9):637-648.
DOI
|
35 |
World Health Organization. Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020; 2021 [cited 2021 Jul 20]. Available from: https://www.who.int/publications/i/item/9789240019003.
|
36 |
World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries; 2018 [cited 2021 Mar 1]. Available from: https://www.who.int/publications/i/item/progress-report-on-access-to-hepatitis-c-treatment.
|
37 |
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1736-1788.
DOI
|
38 |
Schatz E. The importance of civil society involvement in eliminating hepatitis C. EMJ Hepatol 2017;5(1):48-49.
|
39 |
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis; 2016 [cited 2021 Mar 1]. Available from: https://apps.who.int/iris/handle/10665/246177.
|
40 |
World Health Organization. Sixty-seventh World Health Assembly (WHA67.6): hepatitis; 2014 [cited 2021 Mar 1]. Available from: https://www.worldhepatitisalliance.org/sites/default/files/resources/documents/WHA67.6.pdf.
|
41 |
World Health Organization. Global hepatitis report, 2017 [cited 2021 Mar 1]. Available from: https://www.who.int/publications/i/item/global-hepatitis-report-2017.
|
42 |
Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016;150(7):1599-1608.
DOI
|
43 |
Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, et al. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol 2019;4(10):794-804.
DOI
|
44 |
Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med 2017;167(5):311-318.
DOI
|
45 |
Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013;57(Suppl 2):S39-S45.
DOI
|
46 |
Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, Bjornsson ES, et al. Treatment as prevention for hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med 2018;283(5):500-507.
DOI
|
47 |
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705-714.
DOI
|
48 |
Muller D. Interpellation 19.3042: federal funding for the fight against viral hepatitis; 2019 [cited 2021 Jul 15]. Available from: https://www.parlament.ch/de/ratsbetrieb/suche-curia-vista/geschaeft?AffairId=20193042.
|
49 |
Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet 2019;393(10178):1319-1329.
DOI
|
50 |
United Nations Office on Drugs and Crime. World drug report 2017: 29.5 million people globally suffer from drug use disorders, opioids the most harmful [cited 2021 Mar 1]. Available from: https://www.unodc.org/unodc/en/frontpage/2017/June/world-drug-report-2017_-29-5-million-people-globally-sufferfrom-drug-use-disorders--opioids-the-most-harmful.html.
|